ReviewJournal of human hypertension2007
Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
Review in Journal of human hypertension, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial.Chinese medical journal · 2016Trial
- Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study.Journal of clinical hypertension (Greenwich, Conn.) · 2011Trial
- Results of treatment with telmisartan-amlodipine in hypertensive patients.Journal of clinical hypertension (Greenwich, Conn.) · 2009Trial
- Nanosensors in the detection of antihypertension drugs, a golden step for medication adherence monitoring.Heliyon · 2023Review
- Effect of antihypertensive agents - captopril and nifedipine - on the functional properties of rat heart mitochondria.Iranian journal of basic medical sciences · 2016Article
- Phenomics of Vascular Disease: The Systematic Approach to the Combination Therapy.Current vascular pharmacology · 2015Review
- Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling.International journal of hypertension · 2012Article
- Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension.Drugs · 2011Review
- Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension.Integrated blood pressure control · 2011Article
- Combination therapy in hypertension: An update.Diabetology & metabolic syndrome · 2010Article
- Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination.Integrated blood pressure control · 2010Article
- Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.Vascular health and risk management · 2009Review
- Risk-based classification of hypertension and the role of combination therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with hypertension, particularly those with diabetes mellitus, are at heightened risk for cardiovascular and renal disease. Accumulated evidence indicates that the majority of hypertensive patients at high risk will require more than one antihypertensive agent to reach their blood pressure (BP) target. A reasonable strategy is to use agents with complementary mechanisms of action to enhance BP-lowering efficacy and prevent target organ damage. In experimental models, the combination of a calcium channel blocker (CCB) with an agent that blocks the renin-angiotensin system (RAS), an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker, improves measures of endothelial function, inflammation, ventricular remodelling and renal function to a greater degree than these classes given as monotherapy. In clinical trials, calcium channel/RAS blockade combination therapy has been shown to provide greater BP reductions and improve renal function in patients with diabetic and nondiabetic renal disease earlier and to a greater extent than monotherapy. In addition, dual calcium channel/RAS blockade increases arterial compliance, arterial distensibility and flow-mediated vasodilation. Expanding upon extensive research on the benefits of calcium channel blockade and RAS blockade for the prevention of vascular events and preclinical and clinical trial evidence suggests added effects of combination therapy by targeting the underlying mechanisms of hypertensive vascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.